Engineered protein that cuts Alzheimer's-linked brain deposits opens potential therapeutic avenue
· Medical Xpressby The Korea Advanced Institute of Science and Technology (KAIST)
edited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add to Preferred Sources
A KAIST-led research team has found that a protein involved in gene regulation can suppress the harmful aggregation of amyloid-beta, a peptide associated with Alzheimer's disease. The approach also reduced the toxicity of protein aggregates that had already formed.
In experiments using a mouse model of Alzheimer's disease, the treatment reduced protein accumulation in the brain and improved memory recognition, suggesting a possible route toward new therapeutics.
The research team led by Professor Mi Hee Lim from the Department of Chemistry identified a new approach to controlling the aggregation and toxicity of amyloid-beta. The findings were published in Advanced Science.
The study was conducted in collaboration with Professor Seung Jae Lee's team in the Department of Chemistry at Jeonbuk National University, Dr. Chul-Ho Lee and Dr. Kyoung-Shim Kim of the Korea Research Institute of Bioscience and Biotechnology (KRIBB), Dr. Young-Ho Lee of the Korea Basic Science Institute (KBSI), and Dr. Jiyong Park of the Institute for Basic Science (IBS).
One of the hallmarks of Alzheimer's disease is the abnormal aggregation and accumulation of amyloid-beta in the brain. Toxic aggregates formed during this process can damage nerve cells. The team sought to suppress this harmful aggregation and reduce the toxicity of existing aggregates.
A zinc finger protein disrupts toxic aggregation
The team used a zinc finger protein, which is best known for its role in gene regulation. Zinc ions stabilize the protein's folded structure, enabling it to recognize DNA or RNA.
The researchers noted that the protein's surface can also bind to other biomolecules, including proteins. They therefore tested whether it could bind directly to a disease-related protein. Through computer simulations and experiments, they confirmed that ZF2–4, a specific segment of the zinc finger protein, binds directly to regions of amyloid-beta involved in its aggregation.
This binding altered the aggregation of amyloid-beta. The formation of long, entangled toxic amyloid-beta fibrils was suppressed, and aggregates that were less toxic to cells formed instead. When preformed fibrils were treated with ZF2–4, they broke down into short, thin fragments, and their toxicity to cells decreased.
Crossing the blood–brain barrier
The team also developed a method for delivering the protein to the brain. The brain is protected by the blood–brain barrier, which restricts the entry of harmful substances but also makes it difficult for therapeutic proteins to reach the brain. The researchers attached a short peptide to the protein to help it cross the barrier, creating a brain-penetrant variant named ZF2–4–P9.
When ZF2–4–P9 was administered to a transgenic mouse model of Alzheimer's disease, amyloid-beta deposits in the cerebral cortex and the hippocampus each decreased by about 53% compared with the control group. The hippocampus is a brain region important for memory and learning.
The treatment also reduced excessive activation of microglia, the brain's immune cells. Microglia protect the brain, but when they become overly activated, they can contribute to inflammatory responses. In mice treated with the modified protein, microglial activation decreased by about 29% in the cerebral cortex and about 50% in the hippocampus compared with the control group.
Recognition memory gains, but broader benefits unproven
In behavioral tests, the treated mice showed improved recognition memory, which is the ability to distinguish a familiar object from a new one. However, no statistically significant improvements were observed in other memory and learning tests. Because these results were obtained in animal experiments, further studies are needed to evaluate therapeutic efficacy and long-term safety before the approach can be applied to humans.
The study shows that engineering a protein's surface and structure can help control the harmful aggregation of disease-related proteins. The findings could support the development of protein-based therapeutics that target amyloid-beta.
"This study shows that zinc finger proteins, which are well known as tools for gene regulation, can bind directly to disease-causing proteins and suppress their pathological aggregation," said Lim. She added that this principle could help researchers design new protein-based therapeutics that target specific diseases.
Dr. Seongmin Park, a postdoctoral researcher at KAIST (now at KBSI), Yunha Hwang, a Ph.D. candidate at Jeonbuk National University, and Jimin Kwak, a student in the integrated master's and doctoral program at KAIST, served as co-first authors.
Publication details
Seongmin Park et al., Zinc Fingers as Programmable Metalloprotein Scaffolds for Altering Pathogenic Biomolecular Phase Transitions, Advanced Science (2026). DOI: 10.1002/advs.77886
Journal information: Advanced Science
Key medical concepts
Alzheimer's DiseaseAmyloid Beta
Clinical categories
Neurology Provided by The Korea Advanced Institute of Science and Technology (KAIST) Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Engineered protein that cuts Alzheimer's-linked brain deposits opens potential therapeutic avenue (2026, November 5) retrieved 5 November 2026 from https://medicalxpress.com/news/2026-11-protein-alzheimer-linked-brain-deposits.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.